Sanofi has said its radioligand therapy (RLT) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) hit all its objectives in a phase 2 study, setting up possible regulatory filings. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback